BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230622
DTSTAMP:20260429T231800
CREATED:20230607T072453Z
LAST-MODIFIED:20230607T072928Z
UID:30813-1687219200-1687391999@senzagen.com
SUMMARY:MedTech Summit 2023
DESCRIPTION:Biocompatibility for Medical Devices\nTuesday\, 20 June 2023 12:00 – 12:30 \n\nThe GARDskin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\n\nA proof-of-concept study using the GARDskin Medical Device assay to evaluate the skin sensitizing potential of medical device materials using both polar and non-polar extraction vehicles (ISO 10993-12).\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market\n\nSpeaker \n\n\nDr Andy Forreryd\nScientific Liason at SenzaGen
URL:https://senzagen.com/event/medtech-summit-2023/
LOCATION:Brussels\, Belgium
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/06/MedTechSummit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230615
DTEND;VALUE=DATE:20230616
DTSTAMP:20260429T231800
CREATED:20230602T121642Z
LAST-MODIFIED:20230607T084110Z
UID:30803-1686787200-1686873599@senzagen.com
SUMMARY:Skin Sensitization by Altertox Academy
DESCRIPTION:This two days hands-on training is hosted by acCELLerate. \nSkin sensitization is a complex systemic process and since several years\, methods to replace animal tests have been validated and adopted by the OECD in this regard. These tests can be used as part of a weight-of-evidence or integrated using a Defined Approach (DA) to assess Skin Sensitization. \nAgenda\n09:55-10:25 GARD\, SenzaGen\n13:30-14:30 GARD – Case studies\, SenzaGen \nRegistration fee includes the participant booklet\, catering and social dinner. \nRegister here \n 
URL:https://senzagen.com/event/skin-sensitization-by-altertox-academy/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/06/square-accellerate-2023.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230612T160000
DTEND;TZID=Europe/Stockholm:20230612T170000
DTSTAMP:20260429T231800
CREATED:20230524T114652Z
LAST-MODIFIED:20230524T114819Z
UID:30777-1686585600-1686589200@senzagen.com
SUMMARY:Webinar: Time for a Change: Evidence-Based Approaches for the Biological Safety Assessment of Medical Devices
DESCRIPTION:Join this free webinar where Ron Brown\, toxicologist and former FDA risk assessor\, will outline the need for a new and more agile approach for the biological safety assessment of medical devices.\nThis presentation will identify the limitations associated with the current approach\, which largely relies on animal-based tests that may have questionable clinical relevance. It will also describe how new and existing biocompatibility test methods can be evaluated following the principles of an evidence-based toxicology (EBT).\nYou will also learn how to incorporate New Approach Methodologies (NAMs) into a streamlined workflow for the safety assessment of medical devices\, which may decrease the time needed for regulatory approval of a device.\n \nKey takeaways \n\nThe limitations associated with animal-based approaches used to assess the biological safety of medical devices.\nHow to assess the validity of NAMs by using an evidence-based toxicology (EBT) approach.\nHow to incorporate NAMs into a streamlined workflow for medical device safety assessment.\nA case study on the OECD approval of the in vitro assay GARDskin and its applicability for Medical Device assessments supporting both polar and non-polar extraction vehicles (ISO 10993-12).\n\nSpeakers \n \n\nRegister here \n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.
URL:https://senzagen.com/event/webinar-time-for-a-change-evidence-based-approaches-for-the-biological-safety-assessment-of-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/Lime_webinarium_12-JUNE.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230524T160000
DTEND;TZID=Europe/Stockholm:20230524T170000
DTSTAMP:20260429T231800
CREATED:20230510T075904Z
LAST-MODIFIED:20230511T080404Z
UID:30647-1684944000-1684947600@senzagen.com
SUMMARY:Webinar: Using in vitro data in your CE marking submission of Medical Devices
DESCRIPTION:Join this free webinar to learn how you can avoid animal testing and accelerate time to market by using results from in vitro testing for the endpoints of cytotoxicity\, skin irritation and skin sensitization in your biological evaluation for CE-marking of your medical device in line with the EU Medical Device Regulation 2017/745\, the MDR.\n\nKey takeaways \n\nAn introduction to how in vitro testing can be used in the biological evaluation of your medical device with focus on cytotoxicity\, skin irritation and skin sensitization according to MDR.\nThe unique and broad applicability of the OECD approved GARD® assay for skin sensitization testing\, supporting polar and non-polar extraction vehicles as recommended in ISO 10993-12.\nSeveral application examples and a class IIa product CE marking case study supporting ethical test solutions and faster time to market.\nExpert advisory and support in compilation of regulatory documentation for instance gap analysis of ISO standards\, Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER).\n\nSpeakers \n \n\nRegister here\n\n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.
URL:https://senzagen.com/event/webinar-using-in-vitro-data-in-your-ce-marking-submission-of-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/9maj_Lime-_ToxHub_banner_line-e1683643826658.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230513
DTEND;VALUE=DATE:20230514
DTSTAMP:20260429T231800
CREATED:20230511T074528Z
LAST-MODIFIED:20230511T075952Z
UID:30750-1683936000-1684022399@senzagen.com
SUMMARY:ISID 2023 Tokyo Satellite Meeting on Dermal Sensitization & Photoallergenicity
DESCRIPTION:This three-hour event kicks off with a welcome from Expert Panel for Fragrance Safety members Yoshiki Tokura\, MD\, PhD\, Donald V. Belsito\, MD\, and Magnus Bruce\, MD\, PhD\, and an introduction from RIFM’s President\, Anne Marie Api\, PhD\, ATS.\nSession \nDermal Sensitization & Photoallergenicity\n4:05-7:05 pm\, Saturday\, May 13\, 2023\nEminence Hall\, South Tower\, 5th Floor\, Keio Plaza Hotel\, Tokyo \n  \nSpeakers \nPresentations from international experts in toxicology and dermatology will include: \n\nMechanisms of Contact Dermatitis\, Kenji Kabashima\, MD\, PhD\, Kyoto Univ.\nRIFM Dermal Sensitization Program\, Isabelle Lee\, PhD\, RIFM\nOverview RIFM Photoallergy Research Program\, Gretchen Ritacco\, MS\, RIFM\nTrial for development of photo safety assessment system in Shiseido\, Shiho Oeda\, Shiseido\nRIFM-IIVS Photoallergy Research\, Allison Hilberer\, MS\, DABT\, IIVS\nRIFM-SenzaGen Photoallergy Research\, Andy Forreryd\, PhD\, SenzaGen
URL:https://senzagen.com/event/isid-2023-tokyo-satellite-meeting-on-dermal-sensitization-photoallergenicity/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/ISID.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230426T160000
DTEND;TZID=Europe/Stockholm:20230426T170000
DTSTAMP:20260429T231800
CREATED:20230328T144209Z
LAST-MODIFIED:20230330T133759Z
UID:30497-1682524800-1682528400@senzagen.com
SUMMARY:SOT2023 Recap Webinar
DESCRIPTION:In case you missed SenzaGen’s Scientific Session at this year’s SOT\, here is a new opportunity! \nTogether with guest speakers from ExxonMobil Biomedical Sciences Inc. and Research Institute for Fragrance Materials\, Inc. (RIFM)\, SenzaGen’s Andy Forreryd\, PhD will present the latest GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers\, and the potential to further broaden the GARD® applicability. \n\nKey topics\n\n·        Quantitative potency assessments\n·        UVCBs and formulated lubricant products\n·        Agrochemical formulations\n·        Acrylate monomers\n·        Regulatory acceptance according to MDR\n·        New application: Photosensitization \n  \n\nSpeakers\n\nAssessing the Utility of the GARD®skin Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products  \nAllison Greminger\, PhD\, DABT\nToxicology Associate @ExxonMobil Biomedical Sciences Inc.\nDr. Greminger is a board-certified toxicologist who provides scientific and regulatory support to several ExxonMobil Product Solutions businesses. In her current position\, she reviews and evaluates toxicological data to support regulatory compliance for current products\, as well as guide new product development. Dr. Greminger has a specific interest in local hazards relevant for formulated products and has conducted various research on implementing non-animal testing strategies to inform hazard potential. \n  \nAn introduction to photosensitization and why there is a need for development of predictive assays capable of discriminating between photosensitization and photoirritancy \n\nGretchen Ritacco\nPrincipal toxicologist @Research Institute for Fragrance Materials\, Inc. (RIFM)\nGretchen Ritacco leads the Photosafety program at the Research Institute for Fragrance Materials (RIFM). Her duties include evaluating fragrance materials in support of RIFM’s Fragrance Ingredient Safety Assessments and managing RIFM’s photoallergy research. In addition\, she is engaged in collaborations with industry leaders to investigate new approaches to evaluate the photoallergenic potential of fragrance materials. Before RIFM\, Gretchen worked in the Allergy and Asthma Discovery Research group at Schering Plough Research Institute. She evaluated lead development candidates for treating pulmonary disorders\, refined measurement of allergic airway disease\, and investigated markers of airway inflammation. Gretchen is a member of the Society of Toxicology (SOT) and both the European and American Societies of Photobiology (ESP & ASP\, respectively). \n\n  \nNew GARD data on skin sensitization testing: “difficult-to-test” substances and quantitative potency assessment and regulatory testing of Medical Devices \n\n​Andy Forreryd\, PhD\nScientific Liaison @ SenzaGen\nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning. He is also co-developer of the GARD platform for the assessment of chemical sensitizers and is the inventor of two patents related to the technology. \n 
URL:https://senzagen.com/event/2023-sot-recap-webinar/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Lime_RECAP-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230322T080000
DTEND;TZID=Europe/Stockholm:20230323T170000
DTSTAMP:20260429T231800
CREATED:20221109T100611Z
LAST-MODIFIED:20230322T130845Z
UID:30088-1679472000-1679590800@senzagen.com
SUMMARY:2023 SOT Annual Meeting & ToxExpo
DESCRIPTION:Meet us at this year’s SOT\nCome meet us at our booth and join our hosted session to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development. \n \n  \n  \n\nExhibitor-Hosted Session\n\n\n  \n  \n\nPosters\n\n🎫 P117 |  Joint poster with ExxonMobil Biomedical Sciences\n#3016: Mar 20\, 9:00am-10:45am: Assessing the Utility of the Genomic Allergen Rapid Detection (GARDskin) Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products \n🎫 P329 | Joint poster with Research Institute for Fragrance Materials (RIFM)\n#4456: Mar 22\, 10:45am-12:30pm: GARDskin Dose-Response for Photosensitization: Assessment of Reference Photoirritants and Photoallergens \n🎫 P293 | Poster on Medical Device\n#4422: Mar 22\, 10:45am-12:30pm: In Vitro Assays for Assessment of Skin Sensitization Hazard and Potency of Isobornyl Acrylate \n🎫 P151 | Joint poster with International Flavors & Fragrances Inc. (IFF) and Research Institute for Fragrance Materials (RIFM)\n#5050: Mar 23\, 8:30am-11:30am: Gardskin Dose-Response Assay for Pod Determination of Fragrance Materials and Its Application in Conducting Quantitative Risk Assessment (QRA) \n\nExpanded toxicology testing services\n\nAt our booth\, we will introduce you to how you can use in vitro methods for the biological evaluation of medical devices and how we can support you with tailored toxicology advisory services. We will also present our expanded services for in vitro regulatory toxicity testing. \nFind out about our expanded services and expertise\n 
URL:https://senzagen.com/event/2023-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/Newsletter-banner-SOT.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230222T160000
DTEND;TZID=Europe/Stockholm:20230222T170000
DTSTAMP:20260429T231800
CREATED:20230131T145829Z
LAST-MODIFIED:20230131T150057Z
UID:30336-1677081600-1677085200@senzagen.com
SUMMARY:Webinar: Overcoming challenges in skin sensitization testing with GARDskin OECD TG 442E
DESCRIPTION:Free webinar on Feb 22\, 2023 | 4pm CET | 10am EST \nTogether with guest speakers Dr Marco Corvaro\, Technical Team Leader\, Regulatory Toxicology at Corteva Agriscience and Gretchen Ritacco\, Principal Scientist at the Research Institute for Fragrance Materials (RIFM)\, we will discuss the challenges in skin sensitization testing and present new scientific data on agrochemical formulations\, “difficult-to-test” substances\, potency assessment and the potential to further broaden the applicability of the GARD assay to assess the endpoint of photosensitization. \n  \n \n\nAgenda \n\nChallenges in skin sensitization assessment.\nUpdate on the recent OECD approval of GARD®skin TG 442E.\nCase studies on “difficult-to-test” substances and quantitative potency assessment.\nCase study: Investigating the applicability domain of GARD®skin and GARD®potency for agrochemical formulations. Presented by Dr Marco Corvaro\, Corteva Agrisciences.\nNew application: An introduction to photosensitization and why there is a need for development of predictive assays capable of discriminating between photosensitization and photoirritancy.\n\n  \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \nOvercoming challenges in skin sensitization testing with GARD®skin OECD TG 442E  \nThe field of skin sensitization assessment is rapidly evolving. New Approach Methodologies (NAMs) have been developed to increase predictivity\, broaden the applicability and to provide reliable quantitative and qualitative potency assessments. \nAs the first and only genomics and machine learning-based method\, GARDskin has been included into OECD Test Guideline 442E for in vitro skin sensitization. The scientific data published in the TG confirms the high performance and broad applicability of the method\, bringing new opportunities to the field of in vitro skin sensitization testing. \nPhototoxicity is a term used to describe chemicals which has the inherent potential to become photoactivated when exposed to UV-light\, giving rise to otherwise dormant adverse effects. Such effects may include both irritation and sensitization. In terms of risk management\, the distinction of the two types of chemicals is important\, as the hazardous exposure effects of photoirritants can be reduced by concentration limits\, whereas photoallergenic properties currently results in a ban of the chemical at hand. SenzaGen and the Research Institute for Fragrance Materials (RIFM) are collaborating to investigate and develop New Approach Methods (NAMs) for identification and discrimination of photosensitizers from photoirritants. Preliminary data from the incorporation of an UV-exposure step to the original protocol of GARDskin Dose-Response will be illustrated\, and the potential of this approach to simultaneously identify and distinguish between photosensitization and photoirritation will be discussed.  \n\nSpeakers \nDr Marco Covaro\nTechnical Team Leader\, Regulatory Toxicology at Corteva Agriscience\nDr Corvaro has more than 15 years of experience in the safety evaluation of regulated products in a variety of industry sectors. He is a European Registered Toxicologist (ERT) and works as technical lead in Regulatory Toxicology at Corteva. He also acts as the group focal point for activities in the 3R area\, including reduction and alternatives to animal toxicity testing and has been part of several technical expert groups at OECD\, EChA\, ECETOC\, EPAA\, CLE (previously ECPA and EuropaBio) aimed at scientific consensus building and science communication within the regulatory community. \nGretchen Ritacco\nPrincipal Scientist\, Dermatotoxicology at RIFM\nGretchen Ritacco leads the Photosafety program at the Research Institute for Fragrance Materials (RIFM). Her duties include evaluating fragrance materials in support of RIFM’s Fragrance Ingredient Safety Assessments and managing RIFM’s photoallergy research. In addition\, she is engaged in collaborations with industry leaders to investigate new approaches to evaluate the photoallergenic potential of fragrance materials. Before RIFM\, Gretchen worked in the Allergy and Asthma Discovery Research group at Schering Plough Research Institute. She evaluated lead development candidates for treating pulmonary disorders\, refined measurement of allergic airway disease\, and investigated markers of airway inflammation. Gretchen is a member of the Society of Toxicology (SOT) and both the European and American Societies of Photobiology (ESP & ASP\, respectively). \nDr Andy Forreryd\nScientific Liaison at SenzaGen\nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning. He is also co-developer of the GARD platform for the assessment of chemical sensitizers and is the inventor of two patents related to the technology. \n\nREGISTER NOW\n\n 
URL:https://senzagen.com/event/webinar-overcoming-challenges-in-skin-sensitization-testing-with-gardskin-oecd-tg-442e/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/Event-calendar_845x320.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230215
DTEND;VALUE=DATE:20230218
DTSTAMP:20260429T231800
CREATED:20230111T132555Z
LAST-MODIFIED:20230111T154919Z
UID:30279-1676419200-1676678399@senzagen.com
SUMMARY:PCHi 2023 Expo & SHSOT Forum
DESCRIPTION:Personal Care and Homecare Ingredients 2023 Expo & Shanghai Society of Toxicology Forum\n15-17 February 2023 @The China Import and Export Fair Complex\, Guangzhou\, China\nRead More
URL:https://senzagen.com/event/pchi-2023-expo-shsot-forum/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/msg98-1-2022-07-21-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230209
DTEND;VALUE=DATE:20230210
DTSTAMP:20260429T231800
CREATED:20230112T112845Z
LAST-MODIFIED:20230112T114227Z
UID:30297-1675900800-1675987199@senzagen.com
SUMMARY:VitroScreen Seminar on Substance Based Medical Devices
DESCRIPTION:VitroScreen has been a pioneer in developing and proposing pre-clinical experimental protocols on 3D reconstructed human tissue models: they are currently applied to demonstrate the mechanism of action of SBMD and they are relevant to comply with the safety and efficacy requirements of the EU MDR 2017/745. \nThe seminar has the ambition to open a discussion on MDCG 2022-5 with stakeholders involved in Medical Devices (Health Authorities\, Notified Bodies\, Academia\, Industry and ISO representative) analyzing the state of the art of scientific approaches to qualification and classification issues. \nTo view the program and instruction for registration\, please\, click here.
URL:https://senzagen.com/event/vitroscreen-seminar-on-substance-based-medical-devices/
LOCATION:Excelsior Hotel Gallia\, Milan\, Italy
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230124T160000
DTEND;TZID=Europe/Stockholm:20230124T170000
DTSTAMP:20260429T231800
CREATED:20221118T150607Z
LAST-MODIFIED:20230120T152436Z
UID:30122-1674576000-1674579600@senzagen.com
SUMMARY:Webinar: Safety and Efficacy Evaluation of Cosmetic Products and Ingredients
DESCRIPTION:How to integrate innovative in vitro test methods\nIn this joint webinar\, we will present an overview of innovative in vitro methods and how to integrate them into the evaluation of safety and efficacy of cosmetic products and ingredients. The webinar will start with a recorded presentation followed by a live Q&A session. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nKey topics and speakers\n \n\nRegister now
URL:https://senzagen.com/event/webinar-safety-and-efficacy-evaluation-of-cosmetic-products-and-ingredients/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/French-cosmetics-webinar-banner_website-v1-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260429T231800
CREATED:20221021T092257Z
LAST-MODIFIED:20221128T115912Z
UID:29974-1669852800-1670025599@senzagen.com
SUMMARY:2022 Aromadays
DESCRIPTION:Dec 1-2 | Avignon\, Palais des Papes\, France\nMeet us at the 2022 Aromadays conference in Avignon and talk to our specialists regarding the application of the GARD assays for essential oils. \nScientific session\n09:45 CET\, Dec 2\, 2022\nAre there limitations to the applicability of toxicological tests to essential oils ? Focus on the GARD®skin test\nExiste-t-il des limites à l’application des tests toxicologiques aux Huiles Essentielles? Focus sur le test GARD®skin\nCristina ONCINS PALLAS\, Chargée de l’évaluation toxicologique des ingrédients – CONSORTIUM HE\nDr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen\nRead more here
URL:https://senzagen.com/event/2022-aromadays/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/10/logo_aromadays.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221124T080000
DTEND;TZID=Europe/Stockholm:20221125T170000
DTSTAMP:20260429T231800
CREATED:20221102T083023Z
LAST-MODIFIED:20221121T123857Z
UID:30037-1669276800-1669395600@senzagen.com
SUMMARY:2022 SFT
DESCRIPTION:Nov 24-25 | Avignon\, France\nMeet us at the 2022 annual meeting of the French Society of Toxicology in Avignon and talk to our skin sensitization experts regarding the new opportunities the GARD assays have brought to the field. \nWe will also present a poster: “Quantitative sensitizing potency assessment using GARD®skin Dose-Response”. \nPresented by: Dr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen
URL:https://senzagen.com/event/2022-sft/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/logo_sft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221126
DTSTAMP:20260429T231800
CREATED:20220825T140904Z
LAST-MODIFIED:20221114T140547Z
UID:29773-1668988800-1669420799@senzagen.com
SUMMARY:2022 ESTIV
DESCRIPTION:Booth#5 | Nov 21-25 | Sitges (Barcelona)\, Spain\nAre you attending the 2022 ESTIV International Congress? Come meet us at our booth and join our scientific sessions to hear the latest news about GARD and how the assays are used for skin sensitization testing. We will also introduce you to our expanded services for in vitro regulatory toxicity testing and how you can use in vitro methods for the biological evaluation of medical devices. \n\nScientific presentations\n\n“In vitro assessment of skin sensitizing potential of process-related impurities in polymeric materials during product development”\nSpeaker:  Dr Andy Forreryd @SenzaGen \nTuesday\, November 22nd\, 2022\, 11:00-13:00 | Session 3a. Models\, biomarkers and assays for systemic and immune toxicity \n“Biocompatibility of medical devices: eye irritation of preserved and unpreserved eye drops on HCE model”\nSpeaker:  Dr Laura Ceriotti @VitroScreen \nThursday\, November 24th\, 2022\, 11:00-12:40| Session 8a – In vitro methods for safety assessment of medical devices \n\n\nPosters\n\n\nJoint poster with Sonova: #307 – “In vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices”\nPoster presentation by Dr Rose-Marie Jenvert @SenzaGen \nSession 8a. In vitro methods for safety assessment of medical devices \nJoint poster with Coty: #275 – “Effect of a modulator on the skin sensitization potency of cosmetic fragrance formulations”\nPoster presentation by Dr Carine Linossier @Coty \nSession 4b. Local toxicity testing (safety and efficacy) \n  \n 
URL:https://senzagen.com/event/2022-estiv/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/ESTIV_Screenshot-2022-08-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221026T160000
DTEND;TZID=Europe/Stockholm:20221026T170000
DTSTAMP:20260429T231800
CREATED:20220830T120449Z
LAST-MODIFIED:20221017T122725Z
UID:29801-1666800000-1666803600@senzagen.com
SUMMARY:Webinar: How to use in vitro assays in your biological evaluation
DESCRIPTION:In this webinar\, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices\, now offered at our GLP-certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR. \nThe webinar will last around 45 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, make sure to register to get access to the recording. \n  \n  \n\nKey takeaways\n\nAttendees will gain insights into: \n💡 In vitro biocompatibility testing now in ISO 10993 \n💡 GARD® compatible with both saline and oil \n💡 GARD® for quantitative potency assessment during product development \n💡 3Rs strategy in compliance with MDR Rule 21  \n\nSpeaker\n\n \n\nHighly accurate and ethical alternatives \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nOur GLP-certified laboratories offer an in vitro biocompatibility package that includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, providing a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human-relevant results with higher accuracy and fewer false-positive results compared to the rabbit model. \nSkin sensitization with GARD®  \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and  10993-10:2021\, thus mimicking the intended use of the device when in contact with skin.  \n\nRegister now
URL:https://senzagen.com/event/webinar-how-to-use-in-vitro-assays-in-your-biological-evaluation/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/08/Webinar-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221019
DTEND;VALUE=DATE:20221022
DTSTAMP:20260429T231800
CREATED:20220825T135715Z
LAST-MODIFIED:20220825T135806Z
UID:29760-1666137600-1666396799@senzagen.com
SUMMARY:2022 ASCCT
DESCRIPTION:Oct 19-21 | Chapel Hill\, N.C.\,USA\nMore information coming soon!
URL:https://senzagen.com/event/2022-ascct/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/22179-RAD-ASCCT-11th-Annual-Meeting-Graphics-Banner-CROPPED-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221012T160000
DTEND;TZID=Europe/Stockholm:20221012T170000
DTSTAMP:20260429T231800
CREATED:20220920T133458Z
LAST-MODIFIED:20220923T095041Z
UID:29883-1665590400-1665594000@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen’s 2022 ICT Scientific Session
DESCRIPTION:New GARD® data on agrochemicals\,”difficult-to-test” substances and potency assessments\n\n – In vitro skin sensitization testing: New opportunities for hazard and quantitative potency assessment using genomics and machine learning technology\nIn case you missed SenzaGen’s scientific session at this year’s ICT\, we are pleased to offer you a new opportunity! We will present new scientific data on agrochemical formulations generated in collaboration with Corteva Agriscience\, “difficult-to-test” substances and potency assessment. \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \n \n  \n \n  \n\nRegister now
URL:https://senzagen.com/event/webinar-recap-on-senzagens-2022-ict-industry-symposium/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/09/Recap-webinar-banner-for-website_v4-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260429T231800
CREATED:20220707T081238Z
LAST-MODIFIED:20220926T135947Z
UID:29631-1664928000-1665100799@senzagen.com
SUMMARY:2022 Biocompatibility Matters
DESCRIPTION:Oct 5-6 | Copenhagen\, Denmark\nMeet SenzaGen at 2022 Biocompatibility Matters\, a two-day conference in Copenhagen. SenzaGen’s Medical Device specialist and ISO expert Dr Rose-Marie Jenvert will speak on the topic “New approaches to in vitro sensitization – regulatory acceptance”. \n\nKey takeaways:\n\n* An introduction to in vitro assays for skin sensitization\, ISO 10993-10\n* The potential to use polar and non-polar extracts in in vitro assays\n* How in vitro assays can gain regulatory acceptance\n* Case studies on in vitro skin sensitization assessment of medical devices \n\nRead more and register\n\n 
URL:https://senzagen.com/event/2022-biocompatibility-matters/
LOCATION:Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/07/BM-logo@2x-e1622186428171.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220922
DTSTAMP:20260429T231800
CREATED:20220427T123124Z
LAST-MODIFIED:20220916T085253Z
UID:29390-1663718400-1663804799@senzagen.com
SUMMARY:2022 ICT/IUTOX/EUROTOX
DESCRIPTION:2022 International Congress of Toxicology – “Uniting in Toxicology”\n\nDiscussions at this year’s ICT\nNew opportunities for skin sensitization testing with GARDskin OECD TG 442E\n\nCome visit us at our booth and join our industry symposium to learn how the high performance and broad applicability of the GARDskin method bring new opportunities to the field of in vitro skin sensitization testing. We will provide user cases to show how GARD can be used to fill data gaps during regulatory testing and R&D. \n\nIndustry symposium\nNew GARD data on “difficult-to-test” substances and potency assessment\n\nSep 20\, 12:00-13:00 CEST @Room 0.09 Athens\n \nREGISTER HERE TO SECURE YOUR SEAT\n(click the link or fill out the form below)\nFill out my online form.\n \n\nHighlights at our booth #34\nDiscover our expanded in vitro toxicity testing services\n\nDo you have “difficult-to-test” samples or are you looking for quantitative skin sensitizing potency information? Come discuss your testing needs with us and learn more about GARD and our expanded in vitro toxicity testing services for cosmetics\, chemicals and medical devices. \nFIND OUT ABOUT OUR SERVICES AND EXPERTISE
URL:https://senzagen.com/event/2022-ict-iutox-eurotox/
LOCATION:Maastricht
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/04/LIME-banner-v7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220914T143000
DTEND;TZID=Europe/Stockholm:20220914T180000
DTSTAMP:20260429T231800
CREATED:20220825T134032Z
LAST-MODIFIED:20220826T062417Z
UID:29741-1663165800-1663178400@senzagen.com
SUMMARY:2022 MVA MedTech Network meeting
DESCRIPTION:Drug device combination products and substance-based medical devices\nSep 14 | Copenhagen\, Denmark\nMedicon Valley Alliance\, together with member company Innokas Medical\, have the pleasure to invite you to the Medicon Valley Alliance MedTech Network meeting\, on the 14th of September\, focusing on drug-device combination products and substance-based medical devices. \n\nSign up here\n\nThe market for drug-device combination products is growing and it is anticipated that up to one in three medical products in development is a combination of a drug/substance and a MedTech product. Drivers for the growth in combination products is the rise of patients suffering from chronic diseases such as diabetes\, cancer\, and respiratory problems as well as growth in the home-based health care market and technological advancements. \nWhen searching for the correct regulatory approval in the EU the primary mode of action (PMOA) will define the regulatory path for your products. For example\, if the action of your medicinal substance is ancillary\, then your product is regulated as a medical device under MDR\, on the other hand\, if the product is mainly of the medicinal substance the product will be regulated as a medicinal product.  A substance with a therapeutic effect can be either a medicinal product/drug or a medical device\, depending on its primary mechanism of action. \nDeveloping this type of products is associated with a high level of complexity. For combination products\, you need to navigate two of the most intensely regulated pathways in one go: for pharmaceuticals and medical devices. The re-classification of substance-based medical devices according to MDR means a more extensive risk assessment involving scientific evidence of PMOA. \nIn this MVA MedTech Network meeting\, we would like to invite you to hear from experts in the area of developing drug-device combination products and substance-based medical devices as well as hearing from companies sharing their experiences\, challenges and solutions.\nIf you are interested in sharing your company’s approach and experiences with drug-device combination products and/or substance-based medical devices and to speak at the meeting on the 14th of September\, please reach out to Sofia Norås\, sn@mva.org. \nAgenda\n14.30 – 15.00  Registration\, networking and light refreshments\n15.00 – 15.10  Welcome\, Anette Steenberg\, CEO\, Medicon Valley Alliance; Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.10 – 15.15  IP and patents in combination products\, Pernille Winding Gojkovic\, CEO\, Høiberg European Patent Attorneys\n15.15 – 15.45  Challenging development with combination products\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.45 – 16.05  Substance-based medical devices\, Rose-Marie Jenvert\, Product Manager GARD applications SenzaGen\n16.05 – 16.40  Company cases TBC\n16.40 – 17.00  Concluding remarks: Building collaborations between organisations & Q&A to all speakers\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n17.00 – 18.00  Networking
URL:https://senzagen.com/event/2022-mva-medtech-network-meeting/
LOCATION:Medicon Valley Alliance\, Auditorium\, Arne Jacobsens Alle 15 \, 2300 Ørestad City\, Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/220914-medtech-network-banner-1080.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220713T160000
DTEND;TZID=Europe/Stockholm:20220713T170000
DTSTAMP:20260429T231800
CREATED:20220630T072933Z
LAST-MODIFIED:20220825T090554Z
UID:29536-1657728000-1657731600@senzagen.com
SUMMARY:Webinar: OECD update
DESCRIPTION:Join this live webinar led by our skin sensitization specialist Dr Andy Forreryd to learn the features and benefits of GARDskin and how the method can be used to fill data gaps during regulatory testing and product development. \n \nGARDskin approved by OECD\nWe are delighted to announce that SenzaGen’s GARDskin assay has been adopted by OECD as part of Test Guideline 442E for in vitro skin sensitization\, which is a regulatory breakthrough for the GARD technology. As the first and only genomics and machine learning-based method\, GARDskin has been approved for the third key event\, dendritic cell activation. The scientific data published in the TG confirms the high performance and broad applicability of the method\, bringing new opportunities to the field of in vitro skin sensitization testing. \nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \nSpeakers\n \nRegister now
URL:https://senzagen.com/event/webinar-oecd-update/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/06/LInkedIn-versaler-e1656335357210.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220525T160000
DTEND;TZID=Europe/Stockholm:20220525T170000
DTSTAMP:20260429T231800
CREATED:20220504T140953Z
LAST-MODIFIED:20220627T125525Z
UID:29411-1653494400-1653498000@senzagen.com
SUMMARY:Webinar: Medical devices' principal mode of action by physical means
DESCRIPTION:Case studies on 3D reconstructed human tissues\nThis webinar will showcase the opportunities offered by 3D reconstructed human tissues to demonstrate the physical mode of action of medical devices in line with the requirements and ethical criteria of the EU Medical Devices Regulation (MDR) 2017/745. \n\nKey takeaways\n\nAttendees will gain insights into: \n💡 How the principles of the 3Rs are applied in the MDR’s requirements. \n💡 How 3D reconstructed human tissues become a robust tool to define and demonstrate the principal mode of action of medical devices. \n💡 How to assess on a case by case approach the physical mode of action of medical devices according to their different therapeutic areas. \n  \n \nNew approach methodologies (NAMs) are driving the transition from animal testing to science-based decision-making for human risk assessment in the life sciences. This transition is aligned with EU Directive 2010/63 on the protection of animals used for scientific purposes and the principles of the 3Rs. \nWe’ll illustrate how NAMs are applied in the medical devices sector. The principles of the 3Rs were an important source of inspiration for the MDR.  ISO 10993 describing the Biological Evaluation of medical devices mandates that appropriate and scientifically validated in vitro methods be preferred over in vivo methods.  3D reconstructed human epidermis tissues can be used to assess skin irritation of medical device components and extracts (ISO 10993-23:2021). Additionally\, genomic-based test methods have been demonstrated to be promising solutions for the assessment of the skin sensitization potential of medical devices (ISO 10993-10:2021). \nManufacturers are required to provide scientific proof in their technical file for the qualification of their product as MD (MDCG 2022-5). They need to provide state-of-the-art scientific data regarding the principal mode of action of the MD. By definition\, this should be physical\, mechanical\, or chemical and cannot be pharmacological\, immunological\, or metabolic. As a result\, the demonstration of a physical mode of action became an essential requirement. The film-forming properties and bio-adhesivity of an MD can be demonstrated on 3D reconstructed human tissue models on a case-by-case approach to produce evidence of the MD’s physical mode of action. \nVitroScreen has developed and published an experimental procedure on reconstructed human epidermis for film-forming assessment. With this as a basis\, we propose protocols optimized for each specific therapeutic area by selecting the tissues on which the MD is intended to act and defining a treatment procedure that mirrors realistic conditions of use. We will present case studies based on different formulation types suitable for gastroenterology\, gynecology\, ophthalmology\, oral care\, urology\, and the respiratory tract. \n  \n\nSpeakers\n\n \n \n  \n\nRegister now
URL:https://senzagen.com/event/webinar-medical-devices-principal-mode-of-action-by-physical-means/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/05/Website-banner-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220428T160000
DTEND;TZID=Europe/Stockholm:20220428T170000
DTSTAMP:20260429T231800
CREATED:20220331T075055Z
LAST-MODIFIED:20220627T125547Z
UID:29263-1651161600-1651165200@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen’s 2022 SOT Scientific Session
DESCRIPTION:New GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals\n\n – Skin sensitization: using in vitro tools for quantitative potency assessment as an alternative to the Local Lymph Node Assay\nIn case you missed SenzaGen’s scientific session at this year’s SOT\, here is a new opportunity! \nTogether with guest speakers from Takasago and Sonova\, we will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. New GARD data on agrochemical formulations\, fragrance materials\, medical devices and metals will be presented. \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nAgenda\n \n\nRegister now
URL:https://senzagen.com/event/webinar-recap-on-senzagens-2022-sot-exhibitor-hosted-session/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/03/Recap-webinar-banner-for-website-v5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260429T231800
CREATED:20220224T104229Z
LAST-MODIFIED:20220224T105153Z
UID:28967-1649116800-1649375999@senzagen.com
SUMMARY:in-cosmetics Global
DESCRIPTION:The leading global event for personal care ingredients\nApril 5-7 | Porte de Versailles\, Paris | Booth: P102\nMeet SenzaGen and partners PKDERM\, GenEvolutioN\, WatchFrog and CEHTRA at in-cosmetics Global in Paris to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients!
URL:https://senzagen.com/event/in-cosmetics-global-2/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/02/Incosmeticsglobal-2022_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220327
DTEND;VALUE=DATE:20220401
DTSTAMP:20260429T231800
CREATED:20211209T133110Z
LAST-MODIFIED:20220321T111837Z
UID:28283-1648339200-1648771199@senzagen.com
SUMMARY:2022 SOT
DESCRIPTION:Meet us at the 2022 SOT Annual Meeting & ToxExpo\nBooth #1207 @ San Diego Convention Center\, San Diego\, USA\nAre you attending the 2021 Society of Toxicology Annual Meeting? Come join our hosted session and poster presentations to hear the latest news about GARD™ and how the assays are used for skin sensitization testing. We will also introduce you to how you can use in vitro methods for the biological evaluation of medical devices.  \n\nExhibitor hosted session\n\nMar 29\, 10:30-11:30 EDT\, Room 23A\nNew GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals:\nTogether with guest speakers from Takasago and Sonova\, our Scientific Liaison Dr Andy Forreryd will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. \n  \n \nBook mark the session in SOT’s event calendar: \nSkin Sensitization: Using In Vitro Tools for Quantitative Potency Assessment as an Alternative to the Local Lymph Node Assay \n  \n\nPosters\n\nLive poster sessions on Mar 28\, 9:00-10:45 EDT\n🎫 P460 | Applicability domain of GARDskin\nThe GARDskin assay: Investigation of the applicability domain of indirectly acting haptens  \n🎫 P850 | Joint poster with Sonova\nIn vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices  \n🎫 P846 | Joint poster with Risk Science Consortium\nAbility of the GARD assay to replace the GPMT and the LLNA for assessment of the skin sensitization potential of medical devices  \n 
URL:https://senzagen.com/event/2022-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/SOT-2022_small-narrow-green.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220217T160000
DTEND;TZID=Europe/Stockholm:20220217T170000
DTSTAMP:20260429T231800
CREATED:20211209T154800Z
LAST-MODIFIED:20220204T125454Z
UID:28308-1645113600-1645117200@senzagen.com
SUMMARY:Webinar: Safer Medical Devices - In vitro assays as part of your biological evaluation
DESCRIPTION:In this webinar\, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices\, now offered at our GLP certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR. \nThe webinar will last around 45 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, make sure to register to get access to the recording. \nKey topics\n\nHow you can use in vitro assays for biocompatibility testing of medical devices: cytotoxicity\, skin irritation and sensitization.\nThe broad applicability and high accuracy of the GARD sensitization assay\, supporting both polar and non-polar extraction vehicles (ISO 10993-12).\nUser cases on skin sensitization assessment of medical devices.\n\n \nSpeaker\n \n\nHighly accurate and ethical alternatives \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nOur GLP certified laboratories offer an in vitro biocompatibility package that includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, providing a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human-relevant results with higher accuracy and fewer false-positive results compared to the rabbit model. \nSkin sensitization with GARD™ \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and  10993-10:2021\, thus mimicking the intended use of the device when in contact with skin.  \n\nRegister now
URL:https://senzagen.com/event/webinar-biological-evaluation-of-medical-devices-using-in-vitro-methods/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/Banner-without-logo-Cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220120T160000
DTEND;TZID=Europe/Stockholm:20220120T170000
DTSTAMP:20260429T231800
CREATED:20211209T154427Z
LAST-MODIFIED:20220105T083742Z
UID:28303-1642694400-1642698000@senzagen.com
SUMMARY:Webinar: Why Choose GARD™ for Skin Sensitization Testing?
DESCRIPTION:High performance\, broad applicability\, quantitative potency\n\nJoin us for this webinar to get the latest news about the in vitro GARD assays and how they are used to fill data gaps and address challenges in skin sensitization testing\, such as “difficult-to-test” substances\, quantitative potency assessment\, testing of medical devices and solid materials. \n \nKey topics\n\nAn introduction to GARD: How the genomic and machine learning-based technology works and its applications\nCase studies: “Difficult-to-test” samples such as complex mixtures\, pre/pro- haptens and substances with low water solubility\nCase studies: In vitro skin sensitization assessment of medical devices using both saline and oil as extraction vehicles\nCase studies: In vitro quantitative potency assessment as an alternative to LLNA\n\nThe webinar will last around 40 minutes\, followed by a live Q&A. If you can’t attend the live event\, register now to get access to the recording.  \nSpeakers\n \n \n  \nRegister now
URL:https://senzagen.com/event/webinar-why-choose-gard-for-sensitization-testing-2/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/Webinar-banner-v7-cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211214T160000
DTEND;TZID=Europe/Stockholm:20211214T170000
DTSTAMP:20260429T231800
CREATED:20211209T135308Z
LAST-MODIFIED:20211209T135357Z
UID:28292-1639497600-1639501200@senzagen.com
SUMMARY:SaferWorldbyDesign Webinar: Skin safety assessment according to OECD guidelines
DESCRIPTION:Join our skin sensitization expert Dr Andy Forreryd at this SaferWorldbyDesign webinar & panel discussion to learn more about skin safety assessment. \n  \nRead more and register here \n 
URL:https://senzagen.com/event/saferworldbydesign-webinar-skin-safety-assessment-according-to-oecd-guidelines/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/12/banner1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211202
DTEND;VALUE=DATE:20211203
DTSTAMP:20260429T231800
CREATED:20211115T161609Z
LAST-MODIFIED:20211118T123538Z
UID:28127-1638403200-1638489599@senzagen.com
SUMMARY:New Approach Methodologies for Medical Devices
DESCRIPTION:NAMs for Medical Devices: Use of New Approach Methodologies for the Biological Safety Assessment of Medical Devices \nJoin New Approach Methodology Use for Regulatory Application (NURA) on December 2 to learn how you can use the latest in vitro methods for Biological Safety Assessment of medical devices. Engage with industry experts and the Center for Devices and Radiological Health and learn how to use new approaches for risk assessment in the ISO 10993 series\, including updates to ISO 10993-01\, ISO10993-10\, and ISO 10993-23. \nSpeaker \nRose-Marie Jenvert\, PhD SenzaGen\nIn Vitro Skin Sensitization Testing: Updates in ISO 10993-10\, Validation and Regulatory Acceptance
URL:https://senzagen.com/event/new-approach-methodologies-for-medical-devices/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/11/NURA-Medical-Devices-Training.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211118T160000
DTEND;TZID=Europe/Stockholm:20211118T170000
DTSTAMP:20260429T231800
CREATED:20210930T080606Z
LAST-MODIFIED:20211021T122341Z
UID:27696-1637251200-1637254800@senzagen.com
SUMMARY:Webinar: Safety Testing of Cosmetic Products
DESCRIPTION:An Overview of Established Methods and New Approach Methodologies (NAMs)\nIn this joint webinar\,  we will present an overview of established methods and New Approach Methodologies (NAMs) used in the safety testing of cosmetic products. The webinar will start with a recorded presentation followed by a live Q&A session. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nKey topics and speakers\n \n\nRegister now
URL:https://senzagen.com/event/webinar-safety-testing-of-cosmetic-products/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/09/Webinar-banner-_-light-text-cropped.jpg
END:VEVENT
END:VCALENDAR